KLF17P1: A Potential Drug Target and Biomarker (G100133321)

Target Name: KLF17P1

NCBI ID: G100133321

KLF17P1

Other Name(s): Kruppel like factor 17 pseudogene 1

KLF17P1: A Potential Drug Target and Biomarker

Krillain-Livieresen disease (KLDF) is a rare autosomal recessive disorder that is characterized by progressive muscle weakness and wasting. It is caused by a deficiency of the dystrophin gene, which is responsible for maintaining muscle strength and function. In individuals with KLDF, muscle strength and function are rapidly declining, leading to a diagnosis of progressive muscle weakness and wasting.

Recent studies have identified KLF17P1, a gene that is expressed in muscle tissue, as a potential drug target and biomarker for KLDF. KLF17P1 has been shown to play a role in the development and progression of muscle weakness in KLDF individuals.

The KLF17P1 gene is located on the X chromosome and has been shown to encode a protein that is involved in the regulation of muscle strength and function. Studies have shown that individuals with KLDF have reduced levels of dystrophin in their muscle tissue, which is thought to contribute to the progressive muscle weakness and wasting seen in KLDF.

In addition to its role in muscle strength and function, KLF17P1 has also been shown to play a role in the regulation of stem cell proliferation and survival. This may be important for understanding the underlying mechanisms of KLDF, as well as for the development of potential therapeutic approaches.

As a potential drug target, KLF17P1 is an attractive target for drug developers because it is involved in the regulation of multiple physiological processes that are important for human health. In addition, because KLF17P1 is located on the X chromosome, it is expected to be particularly relevant for the treatment of male-based diseases, such as KLDF.

In addition to its potential as a drug target, KLF17P1 has also been identified as a potential biomarker for KLDF. The reduction in dystrophin levels observed in KLDF individuals has been shown to be associated with decreased muscle strength and function. This may be an important biomarker for the diagnosis and evaluation of KLDF.

In conclusion, KLF17P1 is a gene that has the potential to be a drug target and biomarker for KLDF. Further research is needed to understand its role in the development and progression of KLDF, as well as its potential as a therapeutic approach.

Protein Name: Kruppel Like Factor 17 Pseudogene 1

The "KLF17P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLF17P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets